Sign in

ANEB on OTC

Anebulo Pharmaceuticals, Inc.

Anebulo Pharmaceuticals, Inc. is an American pharmaceutical preparations company based in Lakeway.2

Price unavailable

Last updated Oct 21, 2026.

Overview

-$8.5MNet income, fiscal 20253

Compare with another stock.

  • TickerANEB on OTC2
  • IndustryPharmaceutical Preparations2
  • HeadquartersLakeway, United States2
  • Incorporated inDE4
  • Business addressC/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107, Lakeway, Tx 787344
  • Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company4
  • Legal formCorporation2
  • LEI549300XYJQJDSQZ0AY812
  • StatusActive2
  • LEI statusLapsed (not renewed)2
  • Registered addressC/O REGISTERED AGENT SOLUTIONS, INC., 19904 Dover, United States2
  • Registered withDivision of Corporations, Department of State, 79452082

See how the biggest companies compare on our leaderboards

Both oral and IV selonabant are being designed to rapidly reverse the symptoms of cannabis toxicity and reduce the time to recovery.5 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Key numbers, fiscal 2025

-72.8%Return on equity3

Financial statements

Operating income6783-$9.2M in 2025+155% since 2021
-$15.0M-$10.0M-$5.0M02021: -$3.6M-$3.6M20212022: -$6.8M-$6.8M2022+89%2023: -$11.8M-$11.8M2023+72%2024: -$8.3M-$8.3M2024−29%2025: -$9.2M-$9.2M2025+11%
Net income6783-$8.5M in 2025−72% since 2021
-$40.0M-$30.0M-$20.0M-$10.0M02021: -$30.3M-$30.3M20212022: -$6.8M-$6.8M2022−77%2023: -$11.7M-$11.7M2023+72%2024: -$8.2M-$8.2M2024−30%2025: -$8.5M-$8.5M2025+3%
Fiscal year202020212022202320242025
Research and development$2.3M6$3.0M7$5.6M8$3.5M3$4.3M3
Operating expenses$6.8M7$11.8M8$8.3M3$9.2M3
Operating income-$3.6M6-$6.8M7-$11.8M8-$8.3M3-$9.2M3
Interest$11.8K6$200.0K3$400.0K3
Net income-$30.3M6-$6.8M7-$11.7M8-$8.2M3-$8.5M3
Earnings per share-$2.836$0.297-$0.478-$0.323-$0.253
Earnings per share (diluted)$0.297-$0.478-$0.323-$0.253
Shares (weighted, basic)23.3M shares725.1M shares825.8M shares333.8M shares3
Shares (weighted, diluted)23.3M shares725.1M shares825.8M shares333.8M shares3

Compare Anebulo Pharmaceuticals, Inc. with another company

Corporate structure

Anebulo Pharmaceuticals, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of Anebulo Pharmaceuticals, Inc.

  • Anebulo Pharmaceuticals, Inc. Lakeway, Texas, United States

Built from parent and subsidiary links from GLEIF, the Global Legal Entity Identifier Foundation (CC0); major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What Anebulo Pharmaceuticals, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$11.6M3 Jun 30, 2025$3.1M3 Jun 30, 2024+275.8%

Properties, in its own words

We manage our business operations from our principal executive office in Lakeway, Texas, in leased space under a sublease with JFL Capital Management LLC, a company controlled by Joseph F. Lawler, the founder and a director of our company. Since July 2023, we have been paying rent of approximately $400 per month. We believe our present office space is adequate for our current operations and for near-term planned expansion. We recorded rent expense of approximately $4,800 for the fiscal years ended June 30, 2025 and 2024.

Item 2 of the 10-K filed Sep 29, 2025.5

Leadership

Who has led Anebulo Pharmaceuticals, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. Daniel Schneeberger2021
  2. Simon Allen2022
  3. Richard Anthony Cunningham2023–2025

Chief financial officer

  1. James R. Merchant2021
  2. Sandra Gardiner2023
  3. Dan George2023
2025
Board members and other officers (10)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • DirectorKenneth R. Lin named Oct 11, 2022 to Dec 31, 202427

Timeline

  1. Feb 12, 20268-K Results of operations28
  2. Feb 6, 20268-K Listing notice or transfer; Other events29
  3. Jan 29, 20268-K Other events30
  4. Jan 27, 20268-K Other events31
  5. Dec 22, 20258-K Other events32
  6. Nov 13, 20258-K Results of operations33
  7. Sep 29, 20258-K Results of operations34
  8. Sep 12, 20258-K Other events35
  9. Jul 23, 20258-K Other events36
  10. May 13, 20258-K Results of operations37
  11. Apr 15, 20258-K Other events38
  12. Apr 14, 20258-K Bylaws or fiscal year changed39
  13. Oct 11, 2023New chief executive Richard Anthony Cunningham becomes CEO12
  14. Feb 7, 2022New chief executive Simon Allen becomes CEO13
  15. May 6, 2021New chief executive Daniel Schneeberger becomes CEO14

Calendar

When it reported results

  1. Feb 12, 2026Reported quarterly or annual results28
  2. Nov 13, 2025Reported quarterly or annual results33
  3. Sep 29, 2025Reported quarterly or annual results34
  4. May 13, 2025Reported quarterly or annual results37
  5. Feb 14, 2025Reported quarterly or annual results40
  6. Nov 13, 2024Reported quarterly or annual results41
  7. Sep 25, 2024Reported quarterly or annual results42
  8. May 15, 2024Reported quarterly or annual results43

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

166 filings to the SEC since October 2021: 4 annual reports, 14 quarterly reports, 51 major events, 46 insider forms, 5 large holders, 2 private raises, 44 other. The latest 20:

  1. Mar 2, 202615-12G EDGAR
  2. Feb 17, 202625 EDGAR
  3. Feb 13, 2026SCHEDULE 13G/A EDGAR
  4. Feb 12, 202610-Q EDGAR
  5. Feb 12, 20268-K EDGAR
  6. Feb 6, 20268-K EDGAR
  7. Jan 29, 2026SC 13E3/A SC TO-I/A EDGAR
  8. Jan 29, 20268-K EDGAR
  9. Jan 27, 2026SC 13E3/A SC TO-I/A EDGAR
  10. Jan 27, 20268-K EDGAR
  11. Jan 8, 2026CORRESP EDGAR
  12. Jan 8, 2026SC 13E3/A SC TO-I/A EDGAR
  13. Dec 31, 2025UPLOAD EDGAR
  14. Dec 22, 2025SC 13E3 SC TO-I EDGAR
  15. Dec 22, 2025SC TO-I EDGAR
  16. Dec 22, 20258-K EDGAR
  17. Nov 13, 202510-Q EDGAR
  18. Nov 13, 20258-K EDGAR
  19. Oct 14, 2025SC 13E3/A EDGAR
  20. Oct 10, 2025CORRESP EDGAR

The 166 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

5 open-market trades by officers, directors and large owners since October 2021: 5 buys and 0 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Dec 23, 2024English Aron R.DirectorBuy10,101,010$0.99$10.0MForm 4
Dec 17, 202122NW Fund, LP10% ownerBuy400$6.59$2.6KForm 4
Dec 14, 202122NW Fund, LP10% ownerBuy412$5.90$2.4KForm 4
Dec 3, 202122NW Fund, LP10% ownerBuy4,500$5.93$26.7KForm 4
Dec 2, 202122NW Fund, LP10% ownerBuy13,836$5.30$73.3KForm 4

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2024Richard Anthony CunninghamChief Executive Officer54$332.9K$1.7M47
2024Kenneth C. CundyChief Scientific Officer$380.8K$612.2K47
2024Simon AllenFormer President and Chief Executive Officer$131.4K$516.8K47
2024Daniel GeorgePart time Chief Financial Officer54$147.3K$147.3K47
2023Simon AllenFormer President and Chief Executive Officer$472.6K$778.0K47
2023Kenneth C. CundyChief Scientific Officer$361.6K$495.6K47

Funding

Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.

Money received by year$21.6M 2022–2024
Money received by yearMoney received by year, 2022–2024: $21.6M in all. Private raises (Form D) $21.6M.$0$5M$10M$15M2022 · Private raises (Form D): $6.6M202220232024 · Private raises (Form D): $15.0M2024
Figures by year
YearPrivate raises (Form D)Total
2024$15.0M$15.0M
2022$6.6M$6.6M

Private raises

Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.

  1. Dec 22, 2024Raised $15 million in a private offering of equity27 Form D: 1 investor so far Form D
  2. Sep 28, 2022Raised $6.6 million in a private offering of equity48 Form D: $16.2 million offered in all Form D

SEC filer profile

How Anebulo Pharmaceuticals, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARAnebulo Pharmaceuticals, Inc.1
  • CIK0001815974
  • Employer ID (EIN)85-11709505
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; a shell company5
  • Incorporated inDelaware5
  • Fiscal year endsJune 301
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business addressC/O Anebulo Pharmaceuticals, Inc., 1017 Ranch Road 620 South, Suite 107, Lakeway, TX 787341
  • Phone737 203 52701
  • Shares outstanding40,784,731 as of Feb 6, 202610
  • Public float$15.1M as of Dec 31, 20245
  • AuditorEisnerAmper LLP, Iselin, New Jersey PCAOB ID 274; no auditor attestation of internal control over financial reporting5
  • On EDGAR sinceJun 25, 20201
  • Filings204 in all: 8-K (52), 4 (39), 10-Q (15), 3 (15), CORRESP (10), UPLOAD (9), 10-K (5), EFFECT (5)1
    All 39 form types

    SC 13E3/A (5), DEF 14A (4), D (3), PRE 14A (3), 4/A (2), ARS (2), DRSLTR (2), POS AM (2), PRER14A (2), S-1 (2), S-1/A (2), S-8 (2), S-8 POS (2), SC 13E3 (2), SCHEDULE 13D/A (2), SCHEDULE 13G (2), 15-12G (1), 25 (1), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), DEFA14A (1), DEFR14A (1), DRS (1), DRS/A (1), FWP (1), S-3 (1), SC 13D (1), SC TO-I (1), SCHEDULE 13G/A (1)

  • Latest filingsAnnual report (10-K) Sep 29, 2025
    Quarterly report (10-Q) Feb 12, 2026
    Proxy statement (DEF 14A) Mar 6, 2025
    Latest 8-K (8-K) Feb 12, 2026

Securities registered for trading

ClassSymbolExchange
Common StockANEBNasdaq Stock Market LLC

From the cover page of the 10-K filed Sep 29, 2025 (Section 12(b) of the Exchange Act).5

Risk factors and legal proceedings

The risks Anebulo Pharmaceuticals, Inc. names in Item 1A of its 10-K filed Sep 29, 2025: 48 risks under these headings, as written.5

  • Risks Related to our Business, Financial Condition and Capital Requirements
  • We have not generated any revenue since our inception and expect to incur future losses and may never become profitable.
  • We currently have no product revenue and will need to raise additional capital in the future, which may be unavailable to us or may cause dilution or place significant restrictions on our ability to operate.
  • We have a limited operating history as a publicly traded company, and our inexperience could materially and adversely affect us and our stockholders.
  • Our current and future operations substantially depend on our Founder, our Chief Executive Officer, and our ability to hire other key personnel, the loss of any of whom could disrupt our business operations.
  • Risks Related to Our Intellectual Property
  • If we are unable to obtain and maintain patent protection for important aspects of selonabant, or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize products that are similar or identical to ours, and our ability to successfully commercialize our current or future product candidates may be adversely affected.
  • We currently rely on a license from a third party, and in the future may rely on additional licenses from other third parties, in relation to our development of selonabant, and if we fail to comply with our obligations under our current or future intellectual property license agreements or otherwise experience disruptions to our business relationships with our current or any future licensors, we could lose intellectual property rights that are important to our business.
  • We may not be able to protect our intellectual property rights throughout the world, which could negatively impact our business.
  • The expiration or loss of patent protection may adversely affect our future revenues and operating earnings.
  • Risks Related to Product Development, Regulatory Approval, Manufacturing and Commercialization
  • Delays in the completion of, or the termination of, a clinical trial for selonabant, our lead drug candidate, could adversely affect our business.
The other 38 risks
  • If we are not able to obtain any required regulatory approvals for selonabant, we will not be able to commercialize our lead drug candidate and our ability to generate revenue will be limited.
  • Even if we receive regulatory approval for selonabant, our lead drug candidate, we may not be able to successfully commercialize the product and the revenue that we generate from its sales, if any, may be limited.
  • Interim, topline and preliminary data from our preclinical studies or clinical trials may change as more data become available, and are subject to audit and verification procedures that could result in material changes in the final data.
  • Even if we obtain marketing approval for selonabant, we will be subject to ongoing obligations and continued regulatory review, which may result in significant additional expense. Additionally, selonabant could be subject to labeling and other restrictions and withdrawal from the market and we may be subject to penalties if we fail to comply with regulatory requirements or if we experience unanticipated problems with selonabant.
  • Any products we develop may become subject to unfavorable pricing regulations, third-party coverage and reimbursement practices or healthcare reform initiatives, thereby harming our business.
  • Current legislation may increase the difficulty and cost for us to commercialize selonabant and affect the prices we may obtain and our current and future relationships with healthcare professionals, clinical investigators, consultants, patient organizations, customers, CROs and third-party payors.
  • Our lead drug candidate, selonabant, may face competition sooner than expected.
  • Any termination or suspension of, or delays in the commencement or completion of, any necessary studies of selonabant, our lead drug candidate, for any indications could result in increased costs to us, delay or limit our ability to generate revenue and adversely affect our commercial prospects.
  • Clinical drug development involves a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results.
  • We may be exposed to product liability risks, and clinical and preclinical liability risks, which could place a substantial financial burden upon us should we be sued.
  • Selonabant, our lead product candidate, may have undesirable side effects which may delay or prevent marketing approval, or, if approval is received, require it to be taken off the market, require it to include safety warnings or otherwise limit sales of the product.
  • We currently have no marketing and sales organization and we have no direct experience marketing pharmaceutical products. If we are unable to establish our own marketing and sales capabilities, or enter into agreements with third parties to market and sell our products after approval, we may not be able to generate product revenues.
  • New drugs, which may be developed by others, could impair our ability to maintain and grow our business and remain competitive.
  • Recent changes implemented by the United States government, including changes to grant funding and trade policies, may have an adverse effect on our reputation, business, financial condition and results of operations.
  • Risks Related to Our Reliance on Third Parties
  • We depend on third parties in connection with our preclinical testing and clinical trials, which may result in costs and delays that prevent us from obtaining regulatory approval or successfully commercializing selonabant or future product candidates.
  • We will be completely dependent on third parties to manufacture selonabant, and our commercialization of selonabant could be halted, delayed or made less profitable if those third parties fail to obtain manufacturing approval from the FDA or comparable foreign regulatory authorities, fail to provide us with sufficient quantities of selonabant or fail to do so at acceptable quality levels or prices.
  • Our reliance on collaborations with third parties to develop and commercialize selonabant is subject to inherent risks and may result in delays in product development and lost or reduced revenues, restricting our ability to commercialize selonabant and adversely affecting our profitability.
  • Risks Related to Government Regulation of our Industry
  • Legislative or regulatory reform of the healthcare system may affect our ability to sell our products profitably.
  • Clinical trials for selonabant have and may in the future be conducted outside the United States and not under an IND, and where this is the case, the FDA may not accept data from such trials.
  • Risks Related to Ownership of Our Common Stock
  • We intend to seek stockholder approval of a reverse stock split, which is being proposed in connection with our proposed plan to go private and to delist our common stock from the Nasdaq Stock Market and deregister our common stock under the Exchange Act.
  • The trading price and volume of our common stock in the public markets has experienced, and may in the future experience, volatility due to a variety of factors, many of which are beyond our control.
  • Future sales, or the perception of future sales, of a substantial number of our shares of common stock could depress the trading price of our common stock.
  • Our principal stockholders and management own a substantial majority of our stock and will be able to exert significant control over matters subject to stockholder approval.
  • Anti-takeover provisions in our charter documents could discourage, delay or prevent a change in control of our company and may affect the trading price of our common stock.
  • Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the sole and exclusive forum for substantially all disputes between us and our stockholders, and federal district courts will be the sole and exclusive forum for Securities Act claims, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees.
  • We do not expect to pay any dividends on our common stock.
  • General Risk Factors
  • If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed.
  • We are incurring significantly increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance efforts.
  • Changes in accounting principles or guidance, or in their interpretations, could result in unfavorable accounting charges or effects, including changes to our previously filed financial statements, which could cause our stock price to decline.
  • We are an “emerging growth company” and our election to delay adoption of new or revised accounting standards applicable to public companies may result in our financial statements not being comparable to those of some other public companies. As a result of this and other reduced disclosure requirements applicable to emerging growth companies, our securities may be less attractive to investors.
  • Changes in tax laws or regulations that are applied adversely to us or our customers may have a material adverse effect on our business, cash flow, financial condition or results of operations.
  • Our ability to use net operating loss carryforwards and certain other tax attributes to offset future taxable income or taxes may be limited.
  • If securities or industry analysts do not publish or cease publishing research or reports about us, our business or our market, or if they change their recommendations regarding our stock adversely, or if our actual results differ significantly from our guidance, our stock price and trading volume could decline.
  • Health epidemics or pandemics may adversely affect our business, financial condition and results of operations.
  • Unstable market and economic conditions, geopolitical conditions, domestic and foreign trade policies, monetary policies and other factors beyond our control may have serious adverse consequences on our business, financial condition and stock price.
  • Inflation may adversely affect us by increasing our costs.
  • We are subject to stringent and evolving U.S. and foreign laws, regulations, rules, contractual obligations, policies and other obligations related to data privacy and security. Our actual or perceived failure to comply with such obligations could lead to regulatory investigations or actions; litigation (including class claims) and mass arbitration demands; fines and penalties; disruptions of our business operations; reputational harm; loss of revenue or profits; loss of customers or sales; and other adverse business consequences.
  • If our internal information technology systems or sensitive information, or those of our third-party CROs or other contractors or consultants, are or were compromised, we could experience adverse consequences from such compromise, including but not limited to, a material disruption of the development of our product candidates, regulatory investigations or actions, litigation, fines and penalties, reputational harm, loss of revenue or profits, and other adverse consequences.

Legal proceedings

From time to time, we may be a party to litigation or subject to claims incident to the ordinary course of business. We are not currently a party to any material legal proceedings, and our management believes that there are currently no claims or actions pending against us, the ultimate disposition of which could have a material adverse effect on our results of operations or financial condition. However, the results of litigation and claims cannot be predicted with certainty, and regardless of the outcome, litigation can have an adverse impact on us because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.5

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
    SEC EDGAROther events
  31. 31
    SEC EDGAROther events
  32. 32
    SEC EDGAROther events
  33. 33
  34. 34
  35. 35
    SEC EDGAROther events
  36. 36
    SEC EDGAROther events
  37. 37
  38. 38
    SEC EDGAROther events
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48